Quince Therapeutics Inc. has released its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $15.0 million for the period, translating to a net loss of $0.34 per basic and diluted share. The weighted average shares outstanding were 43.9 million. The company reported net cash used in operating activities amounting to $9.6 million. This was primarily driven by the net loss of $15.0 million, adjusted for $3.4 million of non-cash items. General and administrative expenses for the first quarter totaled $4.8 million, which mainly included personnel-related and stock-based compensation expenses, commercial planning, new product planning expenses, and other professional administrative costs. In terms of business operations, Quince Therapeutics is planning to potentially conclude enrollment early for its pivotal Phase 3 NEAT clinical trial in Ataxia-Telangiectasia by the end of June 2025. This strategic decision is intended to align the reporting of topline results with the company's existing cash runway, aiming for early 2026. To date, 63 participants have been enrolled in the trial. The company expects this timeline to provide approximately 80% power to determine a statistically significant difference in the primary endpoint, with plans to submit applications for approval in the U.S. and Europe in the second half of 2026, assuming positive results.